Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 65
TresibaⓇ showed lower day-to-day variability in the
glucose-lowering effect compared to insulin glargine U300
Within-subject variability in steady state
Day-to-day
variability¹
2.0
1.5
1.0
0.5
0.0+
TresibaⓇ
10-12
12-14
14-16
insulin glargine U300
•
16-18
18-20
20-22
22-24
ཨཱུ རཱཾ ༔ ྂ 』
Time interval (hours)
1 Day-to-day variability in 2-hours interval of AUC GIR (variance)
Note: 60 type 1 diabetic patients were enrolled and 57 completed the trial; Inclusion criteria: Age 18-65
years, diagnosis of type 1 diabetes, Fasting C-peptide <0.3 nmol/L, BMI: 18.5-29 kg/m², HbA1c <9%
AUCGIR area under glucose infusion curve
Key results and next step
The day-to-day variability in the glucose-lowering effect
was approximately four-times lower with TresibaⓇ
compared to insulin glargine U300 when evaluated by
within-subject variance for people with type 1 diabetes in
PK/PD trial
• Day-to-day variability was consistently lower for TresibaⓇ
than insulin glargine U300 over the entire 24-hour period
• Insulin glargine U300 showed a statistically significantly*
lower potency compared to TresibaⓇ of approximately 30%
•
Next step: Initiation of large 3b head-to-head trial study
in type 2 diabetes to document clinical benefits including
hypoglycaemia, with expected start in 2017
* p<0.001
novo nordiskView entire presentation